Hiroki Iwashita Selected Research

Type 2 Cyclic Nucleotide Phosphodiesterases

12/2019	TAK-915, a phosphodiesterase 2A inhibitor, ameliorates the cognitive impairment associated with aging in rodent models.
1/2018	Phosphodiesterase 2A Inhibitor TAK-915 Ameliorates Cognitive Impairments and Social Withdrawal in N-Methyl-d-Aspartate Receptor Antagonist-Induced Rat Models of Schizophrenia.
1/2017	Discovery of a Novel Series of Pyrazolo[1,5-a]pyrimidine-Based Phosphodiesterase 2A Inhibitors Structurally Different from N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915), for the Treatment of Cognitive Disorders.
1/2017	Discovery of Clinical Candidate N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915): A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders.
1/2017	Discovery of an Orally Bioavailable, Brain-Penetrating, in Vivo Active Phosphodiesterase 2A Inhibitor Lead Series for the Treatment of Cognitive Disorders.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hiroki Iwashita Research Topics

Disease

5	Cognitive Dysfunction 12/2019 - 01/2017
3	Alzheimer Disease (Alzheimer's Disease) 01/2017 - 10/2009
2	Schizophrenia (Dementia Praecox) 01/2018 - 01/2017
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2017 - 03/2014
2	Tauopathies 03/2014 - 11/2009
1	Dementia (Dementias) 12/2019
1	Memory Disorders (Memory Loss) 12/2019
1	Phototoxic Dermatitis (Phototoxicity) 01/2017
1	Chronic Obstructive Pulmonary Disease (COPD) 06/2012
1	Amyloid Plaque 12/2011
1	Disease Progression 11/2009
1	Inflammation (Inflammations) 07/2006
1	Respiratory Hypersensitivity 07/2006
1	Asthma (Bronchial Asthma) 07/2006

Drug/Important Bio-Agent (IBA)

5	Type 2 Cyclic Nucleotide PhosphodiesterasesIBA 12/2019 - 01/2017
3	PyrazinesIBA 01/2018 - 01/2017
2	TAK-915IBA 12/2019 - 01/2018
2	Cyclic NucleotidesIBA 01/2017 - 01/2017
2	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 01/2017 - 01/2017
2	Glycogen Synthase Kinase 3IBA 12/2011 - 11/2009
1	Scopolamine (Hyoscine)FDA Link 12/2019
1	Adenosine Monophosphate (AMP)IBA 12/2019
1	Muscarinic AntagonistsIBA 12/2019
1	Guanosine Monophosphate (5' Guanylic Acid)IBA 12/2019
1	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 01/2018
1	N-Methylaspartate (NMDA)IBA 01/2018
1	pyrimidineIBA 01/2017
1	Pharmaceutical PreparationsIBA 01/2017
1	Messenger RNA (mRNA)IBA 06/2012
1	Proteins (Proteins, Gene)FDA Link 06/2012
1	Glycogen Synthase (Synthase I)IBA 12/2011
1	Amyloid (Amyloid Fibrils)IBA 12/2011
1	benzofuranIBA 12/2011
1	OxadiazolesIBA 12/2011
1	Glycogen Synthase KinasesIBA 10/2009
1	Chemotactic FactorsIBA 07/2006
1	AllergensIBA 07/2006

Therapy/Procedure

1	Therapeutics 03/2014